Genetic and Molecular Findings of 38 Iranian Patients With Chronic Granulomatous Disease Caused by P47-Phox Defect Publisher Pubmed



Tajik S¹ ; Badalzadeh M^{1, 2} ; Fazlollahi MR¹ ; Houshmand M³ ; Bazargan N⁴ ; Movahedi M⁵ ; Mahlouji Rad M¹ ; Mahdaviani SA⁶ ; Mamishi S⁷ ; Khotaei GT⁷ ; Mansouri D⁸ ; Zandieh F⁹ ; Pourpak Z¹ Show Affiliations
Source: Scandinavian Journal of Immunology Published:2019

Abstract

One of the components of NADPH oxidase is p47-phox, encoded by NCF1 gene. This study aims to find new genetic changes and clinical features in 38 Iranian patients with autosomal recessive chronic granulomatous disease (AR-CGD) caused by NCF1 gene defect. Patients who had abnormal NBT and DHR-1,2,3 assay with loss of p47-phox in Western blotting were included in this study. After recording demographic and clinical data, PCR amplification was performed followed by direct sequencing for all exons and exon-intron boundaries. The most common form of CGD in Iran was AR-CGD due to consanguinity marriages. Among patients with AR-CGD, NCF1 deficiency was found to be more common than other forms. Cutaneous involvements (53%), pulmonary infections (50%) and lymphadenopathy (29%) were more prevalent than other clinical manifestations of CGD. Mutation analysis of NCF1 gene identified five different mutations. Homozygous delta GT deletion (c.75_76delGT) was the most frequent mutation and was detected in more than 63% of families. Six families had a nonsense mutation in exon 7 (c.579G > A). Two novel mutations were found in exon 4 in two families, including a missense mutation (c.328C > T) and a nine-nucleotide deletion (c.331_339delTGTCCCCAC). Genetic detection of these mutations may result in early diagnosis and prevention of possible complications of the disease. This could be useful for timely decision-making for haematopoietic stem cell transplantation and for carrier detection as well as prenatal diagnosis of next children in the affected families. Our findings might help to predict outcomes, raise awareness and help effective treatment in these patients. © 2019 The Foundation for the Scandinavian Journal of Immunology